Overview: CMV IgG Avidity TestIntroduction: The CMV IgG Avidity Test measures IgG antibody avidity to cytomegalovirus to determine infection timing, linked to fever or pregnancy complications. Following 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in virology for patients with suspected CMV infections, particularly in pregnant or immunocompromised individuals.
Other Names: CMV Avidity Assay, Cytomegalovirus IgG Avidity Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: CMV avidity testing began in the 1990s with advances in serology. High-avidity assays emerged in the 2000s, improving accuracy for determining infection timing.
Purpose: Determines timing of CMV infection, guides antiviral therapy, and monitors antibody avidity in patients with fever or pregnancy complications.
Test Parameters: 1. Cytomegalovirus IgG Avidity
Pretest Condition: No fasting required. Collect serum at any time. Report symptoms like fever or pregnancy complications, and list immunocompromising conditions or pregnancy status.
Specimen: 2-5 mL serum (SST). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, pregnancy complications, or immunocompromised states (e.g., HIV, transplant). Include current medications, especially antivirals.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antiviral therapy or fetal monitoring.
Procedural Considerations: Uses an immunoassay to measure CMV IgG avidity. High avidity indicates past infection; low avidity suggests recent infection. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Cross-reactivity with other viruses or early infection can affect avidity results. Hemolysis may degrade samples.
Clinical Significance: Low avidity confirms recent CMV infection, prompting antiviral therapy or fetal monitoring in pregnancy. High avidity suggests past infection, guiding management.
Specialist Consultation: Consult an infectious disease specialist or obstetrician for result interpretation, especially in pregnancy.
Additional Supporting Tests: CMV IgM, CMV PCR, or ultrasound in pregnancy to confirm infection or assess fetal impact.
Test Limitations: False positives may occur with related viruses. Results require clinical correlation.
References: IDSA CMV Guidelines, 2023; Clinical Infectious Diseases, Ljungman P, 2022.
